10x Genomics announced Q3 2026 revenue of $150.7 million, a 1% increase from Q3 2025, driven by strong demand for its new Atera platform and consumables. The company improved its gross margin to 75% and reduced operating expenses by 3%, resulting in a smaller net loss of $19.4 million compared to $27.5 million the previous year. It also introduced Sentira, a new AI-powered cloud analysis platform, positioning itself well for growth in the evolving biology and AI landscape. 10x Genomics raised its full-year 2026 revenue guidance to $625-$635 million, expecting 4-6% growth excluding one-time litigation revenues.
Despite 10x Genomics' revenue growth and improved margins reported for Q3 2026, its stock price on Pluang dropped sharply by 15.60% to USD 56.99 as of Nov 06, 2026 04:11 WIB, moving closer to its 52-week low of USD 13.00 rather than its high of USD 97.74. This contrasts with the company's optimistic full-year guidance and new product launches. The market shows a strong sell sentiment with 88% of orders being sell orders, indicating cautious investor behavior.
